Semiquantitative Analysis of Maximum Standardized Uptake Values of Regional Lymph Nodes in Inflammatory Breast Cancer. Is There a Reliable Threshold for Differentiating Benign from Malignant?

Academic Radiology

Volumn 19, Issue 5, 2012, Pages 535-541

  Carkaci, Selin ^a   Adrada, Beatriz E ^a   Rohren, Eric ^a   Wei, Wei ^a   Quraishi, Mohammad A ^a   Mawlawi, Osama ^a   Buchholz, Thomas A ^a   Yang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Inflammatory breast cancer; Lymph node metastasis; PET CT; SUV; Threshold

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER GRADING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84862822429     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2012.01.001     Document Type: Article

References (41)

1. Haagensen C.D. Diseases of the breast 1971, Saunders, Philadelphia, PA. 2nd ed.
2. Levine P.H., Steinhorn S.C., Ries L.G., et al. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 1985, 74:291-297.
3. Palangie T., Mosseri V., Mihura J., et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994, 30A:921-927.
4. Chevallier B., Asselain B., Kunlin A., et al. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer 1987, 60:897-902.
5. Whitman G.J., Strom E.A. Work up and staging of locally advanced breast cancer. Semin Radiat Onc 2009, 19:211-221.
6. Ueda S., Tsuda H., Asakawa H., et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008, 8:165.
7. Taira T., Ohsumi S., Takabatake D., et al. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Jpn J Clin Oncol 2009, 39:16-21.
8. Yang W.T., Le-Petross H.T., Macapinlac H., et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008, 109:417-426.
9. Kim J., Lee J., Chang E., et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 2009, 33:943-949.
10. Heusner T.A., Kuemmel S., Hahn S., et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009, 36:1543-1550.
11. Chae B.J., Bae J.S., Kang B.J., et al. Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer. Jpn J Clin Oncol 2009, 39:284-289.
12. Monzawa S., Adachi S., Suzuki K., et al. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl Med 2009, 23:855-861.
13. Alberini J.L., Lerebours F., Wartski M., et al. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009, 115:5038-5047.
14. Carkaci S., Macapinlac H.A., Cristofanilli M., et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009, 50:231-238.
15. Johnson M.S., Gonzales M.N., Bizila S. Responsible conduct of radiology research. Part V. The Health Insurance Portability and Accountability Act and Research. Radiology 2005, 237:757-764.
16. Wahl R.L., Siegel B.A., Coleman R.E., et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004, 22:277-285.
17. Veronesi U., De Cicco C., Galimberti V., et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007, 18:473-478.
18. Dirix L.Y., Van Dam P., Prove A., et al. Inflammatory breast cancer: current understanding. Curr Opin Oncol 2006, 18:563-571.
19. Schirrmeister H., Kuhn T., Guhlmann A., et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001, 28:351-358.
20. Yutani K., Shiba E., Kusuoka H., et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000, 24:274-280.
21. Adler L.P., Faulhaber P.F., Schnur K.C., et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro- D-glucose (FDG) PET. Radiology 1997, 203:323-327.
22. Smith I.C., Ogston K.N., Whitford P., et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy- D-glucose. Ann Surg 1998, 228:220-227.
23. Greco M., Crippa F., Agresti R., et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001, 93:630-635.
24. Gil-Rendo A., Zornoza G., García-Velloso M.J., et al. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006, 93:707-712.
25. Van der Hoeven J.J., Hoekstra O.S., Comans E.F., et al. Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002, 236:619-624.
26. Wahl R.L., Kaminski M.S., Ethier S.P., et al. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in the lymph nodes. J Nucl Med 1990, 31:1831-1835.
27. Avril N., Dose J., Janicke F., et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996, 88:1204-1209.
28. Lovrics P.J., Chen V., Coates G., et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004, 11:846-853.
29. Crippa F., Agresti R., Seregni E., et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998, 39:4-8.
30. Lavayssière R., Cabée A., Filmont J. Positron emission tomography (PET) and breast cancer in clinical practice. Eur J Radiol 2009, 69:50-58.
31. Fehr M.K., Hornung R., Varga Z., et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004, 10:89-93.
32. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000, 18:3495-3502.
33. Lim H.S., Yoon W., Chung T.W., et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007, 27(suppl):S197-S213.
34. Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 223:829-838.
35. Singletary S.E., Greene F.L. Revision of breast cancer staging: the 6th edition of the TNM classification. Semin Surg Oncol 2003, 21:53-59.
36. Wahl R.L., Beanlands R.S.B. Principles and practice of PET and PET/CT 2009, Lippincott Williams & Wilkins, Philadelphia, PA. 2nd ed.
37. Reed V.K., Cavalcanti J.L., Strom E.A., et al. Risk of subclinical micrometastatic disease in the supraclavicular nodal bed according to the anatomic distribution in patients with advanced breast cancer. Int J Radiat Oncol Biol Phys 2008, 71:435-440.
38. Klaeser B., Wiederkehr O., Koeberle D., et al. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007, 18:1329-1334.
39. Port E., Yeung H., Gonen M., et al. 18-2-Fluoro-2-deoxy-d-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 2006, 13:677-684.
40. Keyes J.W. SUV: standard uptake or silly useless value?. J Nucl Med 1995, 36:1836-1839.
41. Adams M.C., Turkington T.G., Wilson J.M., et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010, 195:310-320.